Ohe Y - Search Results

1

Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients.

Mizuno T, Yoshida T, Sunami K, Koyama T, Okita N, Kubo T, Sudo K, Shimoi T, Ueno H, Saito E, Katanoda K, Shibata T, Yonemori K, Okusaka T, Boku N, Ohe Y, Hiroshima Y, Ueno M, Kuboki Y, Doi T, Nakamura K, Kohno T, Yatabe Y, Yamamoto N. Mizuno T, et al. Among authors: ohe y. Jpn J Clin Oncol. 2021 Dec 1;51(12):1757-1760. doi: 10.1093/jjco/hyab159. Jpn J Clin Oncol. 2021. PMID: 34622931

2

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.

Borghaei H, Ciuleanu TE, Lee JS, Pluzanski A, Caro RB, Gutierrez M, Ohe Y, Nishio M, Goldman J, Ready N, Spigel DR, Ramalingam SS, Paz-Ares LG, Gainor JF, Ahmed S, Reck M, Maio M, O'Byrne KJ, Memaj A, Nathan F, Tran P, Hellmann MD, Brahmer JR. Borghaei H, et al. Among authors: ohe y. Ann Oncol. 2023 Feb;34(2):173-185. doi: 10.1016/j.annonc.2022.11.006. Epub 2022 Nov 19. Ann Oncol. 2023. PMID: 36414192 Free article.

3

Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.

Chmielecki J, Gray JE, Cheng Y, Ohe Y, Imamura F, Cho BC, Lin MC, Majem M, Shah R, Rukazenkov Y, Todd A, Markovets A, Barrett JC, Hartmaier RJ, Ramalingam SS. Chmielecki J, et al. Among authors: ohe y. Nat Commun. 2023 Jun 1;14(1):3179. doi: 10.1038/s41467-023-38999-0. Nat Commun. 2023. PMID: 37263992 Free PMC article. No abstract available.

4

Phase I/II study of 3-week cycle cisplatin-gemcitabine in advanced non-small cell lung cancer.

Kusaba H, Tamura T, Shimoyama T, Hotta K, Inoue A, Nokihara H, Ueda Y, Akiyama Y, Yamamoto N, Sekine I, Kunitoh H, Ohe Y, Kodama T, Saijo N. Kusaba H, et al. Among authors: ohe y. Jpn J Clin Oncol. 2002 Feb;32(2):43-7. doi: 10.1093/jjco/hyf013. Jpn J Clin Oncol. 2002. PMID: 11948227 Clinical Trial.

5

Tumor response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients.

Watanabe H, Yamamoto S, Kunitoh H, Sekine I, Yamamoto N, Ohe Y, Tamura T, Kodama T, Sugimura K, Saijo N. Watanabe H, et al. Among authors: ohe y. Cancer Sci. 2003 Nov;94(11):1015-20. doi: 10.1111/j.1349-7006.2003.tb01394.x. Cancer Sci. 2003. PMID: 14611681 Free PMC article.

6

Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer.

Watanabe H, Yamamoto N, Tamura T, Shimoyama T, Hotta K, Inoue A, Sawada M, Akiyama Y, Kusaba H, Nokihara H, Sekine I, Kunitoh H, Ohe Y, Kodama T, Saijo N. Watanabe H, et al. Among authors: ohe y. Jpn J Clin Oncol. 2003 Dec;33(12):626-30. doi: 10.1093/jjco/hyg116. Jpn J Clin Oncol. 2003. PMID: 14769840

7

Randomized trial of oral versus intravenous antibiotics in low-risk febrile neutropenic patients with lung cancer.

Niho S, Ohe Y, Goto K, Ohmatsu H, Matsumoto T, Kubota K, Kakinuma R, Nishiwaki Y. Niho S, et al. Among authors: ohe y. Jpn J Clin Oncol. 2004 Feb;34(2):69-73. doi: 10.1093/jjco/hyh019. Jpn J Clin Oncol. 2004. PMID: 15067098 Clinical Trial.

8

Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials.

Sekine I, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Saijo N. Sekine I, et al. Among authors: ohe y. Cancer Treat Rev. 2004 Jun;30(4):359-68. doi: 10.1016/j.ctrv.2003.12.006. Cancer Treat Rev. 2004. PMID: 15145510 Review.

9

Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.

Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Tamura T, Kodama T, Saijo N. Takano T, et al. Among authors: ohe y. Lung Cancer. 2004 Jul;45(1):93-104. doi: 10.1016/j.lungcan.2004.01.010. Lung Cancer. 2004. PMID: 15196739 Clinical Trial.

10

Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer.

Sekine I, Noda K, Oshita F, Yamada K, Tanaka M, Yamashita K, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Sumi M, Saijo N. Sekine I, et al. Among authors: ohe y. Cancer Sci. 2004 Aug;95(8):691-5. doi: 10.1111/j.1349-7006.2004.tb03331.x. Cancer Sci. 2004. PMID: 15298734 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

729 results

Search Page

Filters